HIV drug AZTTP into the brain

Drug delivered: AZTTP, anti-HIV drug
Innovation: Delivering drugs beyond the blood-brain barrier
Research organization: Florida International University

Researchers at Florida International University deployed nanotech recently to send HIV drugs across the blood-brain barrier. Using a "revolutionary" technique, according to the university, the scientists used magnetoelectric nanoparticles to deliver an increased level of the anti-HIV drug AZTTP to the brain.

Crossing the blood-brain barrier is one of those lofty goals in drug delivery that has stumped researchers in the past, but getting AZTTP to the brain is crucial to keeping viruses such as AIDS at bay. By using a magnetoelectric-driven nanoparticle, though, a current triggers the release of the drug where it is needed, as opposed to previous delivery methods, which sent AZTTP to the liver, lungs and other organs first.

The use of magnetoelectricity to trigger delivery in the brain can help treat other diseases, as well, such as Alzheimer's, Parkinson's, epilepsy, muscular dystrophy, meningitis, chronic pain and some types of cancer.

HIV drug AZTTP into the brain

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.